At UCB, we’re focused on helping patients live their best lives. We aim to connect targeted patient populations to cutting-edge science and, in doing so, deliver improved, differentiated experiences to people with the highest unmet needs. September is Immune Thrombocytopenia (ITP) Awareness month, so we’re shining a spotlight on ITP, a rare disease previously known as idiopathic thrombocytopenic purpura.

At UCB, how we do science – from discovery to development to delivery – has been transformed and redesigned around understanding the patient and their individual experience. For specific patient populations new to UCB – like Myasthenia gravis (MG) – this is especially important because no two experiences of this rare, neuromuscular condition are alike. In honor of Myasthenia Gravis Awareness Month, join us as we shine a spotlight to help spread awareness and empower people living with MG.

For International Rare Disease Day, our Global Head of the Rozimab Mission, Chris Clark, shares insights about how UCB is leveraging and growing our capabilities to deliver value for specific patient populations new to UCB. Read the full article on LinkedIn.